US FDA completes inspection of Lupin's Tarapur facility

Pharma major Lupin Limited announced the completion of the United States Food and Drug Administration (FDA) inspection carried out at its Tarapur manufacturing (API) facility.

The inspection was carried out between September 16 to September 20, 2019, the company said.

The company further added that inspection at the Tarapur facility closed with three observations.

The company is confident of addressing them satisfactorily.

Comments

Popular posts from this blog

Updated Ph. Eur. Chapter on plastic containers

Dr. Stephen Hahn Nominated to Head FDA